title: Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte).
abstract: BACKGROUND
  To evaluate the effects of chemotherapy dose intensity (DI) on outcome in patients with aggressive lymphoma, the received relative DI (received RDI) is usually calculated using Hryniuk's model. We applied this model to a selected patient subgroup included in the LNH87 protocol (LNH87-2 protocol), who had been treated with the ACVB induction regimen.
  
  
  METHODS
  Patients aged < 55 who had at least one of the following prognostic factors: performance status (PS) > or = 2, number of extranodal sites > or = 2, tumor burden > or = 10 cm, bone marrow or central nervous system involvement, and Burkitt's or lymphoblastic histologic subtype, were included in this study. Actual DI was calculated using the definition of DI as mg/m2/week previously described by Hryniuk.
  
  
  RESULTS
  Eighty-seven of the 311 patients included in the study (28%) presented a RDI below 70% of the theoretical DI. We demonstrated a decreased response rate (65% vs. 79%, p = 0.01) and shorter overall 2-year survival (61% vs. 72%, p = 0.02) in patients receiving a DI < 70%. This difference was still significant when the multiparametric analysis was used (p = 0.004).
  
  
  CONCLUSIONS
  Results obtained when this model was applied to aggressive lymphoma patients included in the LNH-87 protocol led to the demonstration of a strong relationship between received RDI and survival.
authors.affiliation: Départment de Biostatistique et Informatique Médicale, Hôpital Saint-Louis, Paris, France.
authors.forename: E
authors.initials: E
authors.lastname: Lepage
authors.forename: C
authors.initials: C
authors.lastname: Gisselbrecht
authors.forename: C
authors.initials: C
authors.lastname: Haioun
authors.forename: C
authors.initials: C
authors.lastname: Sebban
authors.forename: H
authors.initials: H
authors.lastname: Tilly
authors.forename: A
authors.initials: A
authors.lastname: Bosly
authors.forename: P
authors.initials: P
authors.lastname: Morel
authors.forename: R
authors.initials: R
authors.lastname: Herbrecht
authors.forename: F
authors.initials: F
authors.lastname: Reyes
authors.forename: B
authors.initials: B
authors.lastname: Coiffier
mesh_terms: D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage; D016026:Bone Marrow Transplantation; D002330:Carmustine / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005602:France; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality / Q000628:therapy; D008727:Methotrexate / Q000008:administration & dosage; D008775:Methylprednisolone / Q000008:administration & dosage; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D011239:Prednisolone / Q000008:administration & dosage; D011379:Prognosis; D012074:Remission Induction; D015996:Survival Rate; D014182:Transplantation, Autologous; D014751:Vindesine / Q000008:administration & dosage
chemical_list: D000903:Antibiotics, Antineoplastic; D001761:Bleomycin; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D008942:Mitoxantrone; D014751:Vindesine; D002330:Carmustine; D008775:Methylprednisolone; D008727:Methotrexate